Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 11/20 | 0.74 |
| ▸ | EGFR | P00533 | 9/20 | 0.71 |
| ▸ | KIT | P10721 | 8/20 | 0.70 |
| ▸ | CSF1R | P07333 | 6/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22024687 | 0.89 | BRAF (0.76) | BRAFEGFRKITCSF1R | |
| SCHEMBL3563190 | 0.88 | BRAF (0.80) | BRAFEGFRKITCSF1R | |
| SCHEMBL22024526 | 0.88 | BRAF (0.73) | BRAFEGFRKITCSF1R | |
| SCHEMBL17537391 | 0.87 | KIT (0.80) | BRAFEGFRKITCSF1R | |
| SCHEMBL22024683 | 0.87 | BRAF (0.75) | BRAFEGFRKITCSF1R | |
| SCHEMBL17313595 | 0.86 | KIT (0.74) | BRAFEGFRKITCSF1R | |
| SCHEMBL3561769 | 0.86 | KIT (0.76) | BRAFEGFRKITCSF1R | |
| SCHEMBL22024682 | 0.85 | BRAF (0.82) | BRAFEGFRKITCSF1R | |
| SCHEMBL24737192 | 0.85 | KIT (0.78) | BRAFEGFRKITCSF1R | |
| SCHEMBL21943581 | 0.85 | KIT (0.78) | BRAFEGFRKITCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3299358-A1 | AMIDE DERIVATIVE AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2018-03-28 | — | — | EP | disclosed |
| EP-1702917-B1 | AMIDE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO LTD (JP) | 2017-08-02 | — | — | EP | disclosed |
| US-7728131-B2 | 3-difluoromethyl-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide, having excellent tyrosine kinase inhibitory activity, used as therapeutic agent for leukemia | NIPPON SHINYAKU CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| CN-100526298-C | Amide derivative and pharmaceutical | NIPPON SHINYAKU CO LTD (JP) | 2009-08-12 | — | — | CN | disclosed |
| CN-101456841-A | Amide derivative and medicine | NIPPON SHINYAKU CO LTD (JP) | 2009-06-17 | — | — | CN | disclosed |
| US-20080293940-A1 | Amide Derivative and Medicine | NIPPON SHINYAKU CO., LTD. (JP) | 2008-11-27 | — | — | US | disclosed |
| CN-1898208-A | Amide derivative and pharmaceutical | NIPPON SHINYAKU CO LTD (JP) | 2007-01-17 | — | — | CN | disclosed |
| EP-1702917-A1 | AMIDE DERIVATIVE AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2006-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293940-A1 | Amide Derivative and Medicine | ABL2, ABL1, BCR | BRAF 114/4885EGFR 66/4885KIT 1217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.